West Pharmaceutical
355 hedge funds and large institutions have $6.76B invested in West Pharmaceutical in 2018 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 132 increasing their positions, 102 reducing their positions, and 51 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
29% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 102
4% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 51
0% more funds holding
Funds holding: 355 → 355 (0)
0.06% less ownership
Funds ownership: 94.09% → 94.03% (-0.06%)
21% less capital invested
Capital invested by funds: $8.52B → $6.76B (-$1.75B)
71% less call options, than puts
Call options by funds: $2.39M | Put options by funds: $8.11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$97.8M |
| 2 |
BlackRock
New York
|
+$32.4M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$30.2M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$25.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
-$74.3M |
| 2 |
Neuberger Berman Group
New York
|
-$25.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$24.2M |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
-$19.3M |
| 5 |
FQ
First Quadrant
Glendale,
California
|
-$18.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
401
EARNEST Partners
Atlanta,
Georgia
| – | -$2K | -20 | Closed |
|
|
CAG
402
Csenge Advisory Group
Clearwater,
Florida
| – | -$1K | -14 | Closed |
|
|
WC
403
Whitney & Co
Rochester,
New York
| – | -$1K | -12 | Closed |
|
|
TL
404
TrueWealth LLC
Atlanta,
Georgia
| – | -$1K | -11 | Closed |
|
|
TC
405
Trilogy Capital
Irvine,
California
| – | -$1K | -7 | Closed |
|
WST Hedge Fund Activity: Q4 2018 in Review
355 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q4 2018, worth a combined $6.76B — down 21% from $8.52B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new WST positions and 51 closed out — a net gain of 2 holders — while 132 added to existing stakes and 102 trimmed.
The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $97.8M. The largest seller was William Blair Investment Management, cutting an estimated $74.3M.
- 355 institutional investors held West Pharmaceutical (WST) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $6.76B of West Pharmaceutical stock for Q4 2018, down 21% quarter-over-quarter.
- 53 funds opened new West Pharmaceutical positions in Q4 2018 and 51 closed out, a net change of +2 holders.
- The largest West Pharmaceutical buyer in Q4 2018 was Capital Research Global Investors, an estimated $97.8M added.
- The largest West Pharmaceutical seller in Q4 2018 was William Blair Investment Management, an estimated $74.3M sold.
Based on aggregated 13F filings for Q4 2018.